Brands
Sun Pharma launches ‘Heart ke Liye 8’ heart health drive
New campaign urges daily habits to build a stronger heart
MUMBAI: Sun Pharmaceutical Industries Limited has launched its ‘Heart ke Liye 8 – Making India Heart Strong’ campaign, urging Indians to prioritise heart health through simple, consistent daily actions.
The initiative comes at a crucial time. Cardiovascular disease accounts for nearly one-fifth of global heart-related deaths, with Indians often affected almost a decade earlier than many Western populations. The campaign reinforces a clear message: heart health is not built overnight, but through everyday choices.
Speaking on the launch, Sun Pharma senior vice president, marketing and sales Shailesh Joshi, said the company believes prevention is just as important as treatment. He noted that the campaign aims to spark regular conversations around heart health and encourage people to adopt small habits that can make a lasting difference.
At the centre of the campaign is the ‘Heart-strong Man’, a relatable and optimistic character symbolising a well-cared-for heart. The tone remains positive and practical, encouraging individuals to take charge of their wellbeing without fear. The campaign film has been created in multiple Indian languages to ensure wider accessibility.
The initiative is anchored around eight essential pillars of heart health, including eating better, staying physically active, managing weight, keeping blood pressure, blood sugar and cholesterol in check, avoiding tobacco, going for regular health check-ups, managing stress, and getting quality sleep.
Beyond awareness, the company’s Making India Heart Strong initiative takes an integrated approach to prevention and response. Sun Pharma organises around 10,000 heart screening camps annually, screening over 1.2 lakh people each year.
In addition, it conducts CPR training for more than 1.5 lakh individuals annually to strengthen emergency preparedness, while also investing in evidence generation to improve risk assessment and patient outcomes.
Its patient education efforts further extend to more than 15 million individuals every year through in-clinic print materials and awareness programmes, contributing to a broader, long-term effort to reduce the cardiovascular disease burden in India.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
